IFNA1 and psoriasis: To investigate the direct effects of TYK2i treatment on IFNα responses in β cells, islets isolated from human organ donors were treated with IFNα in the presence or absence of BMS-986165 (deucravacitinib), which is FDA-approved for use in psoriasis (33).